Cowen Upgrades PerkinElmer to Outperform | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Cowen & Co. today upgraded PerkinElmer's stock, citing favorable end-market exposure and year-over-year comparisons that could result in mid-single digit revenue growth in 2014.

Analyst Doug Schenkel upgraded the company's stock to Outperform from Market Perform, and increased the price target on its shares to $47 from $35.20.

In afternoon trading on Monday, PerkinElmer's shares on the Nasdaq was up 1 percent to $41.68.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.